Disease · MONDO_0005229
Comparisons in its trials31
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 31
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dalbavancin vs Standard of Care: Frequency of All-Cause Mortality (A Component of DOOR) | 4 of 100 | 4 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of AEs Leading to Study Drug Discontinuation | 3 of 100 | 12 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of Clinical Efficacy | 73 of 100 | 72 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of SAEs (A Component of DOOR) | 40 of 100 | 34 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of AEs Leading to Study Drug Discontinuation (A Component of DOOR) | 3 of 100 | 12 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of Infectious Complications (A Component of DOOR) | 13 of 100 | 12 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: deaths from any cause | 5 of 100 | 4 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of Clinical Failure (A Component of DOOR) | 20 of 100 | 22 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: Frequency of SAEs | 43 of 100 | 37 of 100 | 200 | NCT04775953 | Trial comparisons |
| Dalbavancin vs Standard of Care: serious adverse events | 43 of 100 | 37 of 100 | 200 | NCT04775953 | Trial comparisons |
| Part A - Group 1 vs Part A - Group 2: Proportion of Patients With Nephrotoxicity | 12 of 91 | 32 of 85 | 176 | NCT03894046 | Trial comparisons |
| Part A - Group 1 vs Part A - Group 2: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population | 12 of 63 | 20 of 62 | 125 | NCT03894046 | Trial comparisons |
| Tedizolid Phosphate (Sivextro, BAY1192631) vs Linezolid: serious adverse events | 7 of 83 | 4 of 41 | 124 | NCT01967225 | Trial comparisons |
| Telavancin vs Standard of Care: deaths from any cause | 3 of 58 | 5 of 60 | 118 | NCT02208063 | Trial comparisons |
| Telavancin vs Standard of Care: serious adverse events | 16 of 58 | 13 of 60 | 118 | NCT02208063 | Trial comparisons |
| Imipenem-Relebactam Arm vs Standard of Care (SOC) Arm: Infection-related Mortality in the MITT Analysis Set at LFU. | 0 of 49 | 0 of 50 | 99 | NCT04983901 | Trial comparisons |
| Imipenem-Relebactam Arm vs Standard of Care (SOC) Arm: Infection-related Mortality in the MITT Analysis Set at TOC. | 0 of 49 | 0 of 50 | 99 | NCT04983901 | Trial comparisons |
| Imipenem-Relebactam Arm vs Group II (Cefepime, Meropenem, Piperacillin/Tazobactam): deaths from any cause | 1 of 49 | 4 of 50 | 99 | NCT04983901 | Trial comparisons |
| Imipenem-Relebactam Arm vs Standard of Care (SOC) Arm: 30-Day All-cause Mortality in the MITT Analysis Set. | 2 of 49 | 3 of 50 | 99 | NCT04983901 | Trial comparisons |
| Imipenem-Relebactam Arm vs Group II (Cefepime, Meropenem, Piperacillin/Tazobactam): serious adverse events | 30 of 49 | 29 of 50 | 99 | NCT04983901 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005229/comparisons